Stock 1349 SHANGHAI FUDAN-ZHANGJIANG BIO-PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

Equities

1349

CNE1000000W4

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:20 2024-04-26 am EDT 		5-day change 1st Jan Change
2.17 HKD +2.36% Intraday chart for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. +4.33% -14.90%
Apr. 22 Shanghai Fudan-Zhangjiang Buys Structured Deposits Worth 200 Million Yuan MT
Apr. 01 Fudan-Zhangjiang Bio Sees Profit, Revenue Drop in 2023 MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Shanghai Fudan-Zhangjiang Buys Structured Deposits Worth 200 Million Yuan
MT
Fudan-Zhangjiang Bio Sees Profit, Revenue Drop in 2023
MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Proposes Final Ordinary Dividend for the Year Ended December 31, 2023, Payable on August 26, 2024
CI
Fudan-Zhangjiang Bio's 2023 Profit Falls
MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Fudan-Zhangjiang Bio-Pharmaceutical to Subscribe for Deposit Products Worth 357 Million Yuan
MT
Fudan-Zhangjiang Invests 357 Million Yuan in Ping An Bank Structured Deposit Products
MT
Fudan-Zhangjiang Unit's Clinical Trial Application for Glioma Visualization Agent Accepted in China
MT
Chinese Regulator Accepts Fudan-Zhangjiang Bio-Pharmaceutical's Application for Bladder Cancer Visualization Drug Trial
MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Receives the Acceptance Notice for the Application
CI
Chinese Regulator NMPA Grants Acceptance Notice for Shanghai Fudan-Zhangjiang's Investigational Drug
MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Receives the Acceptance Notice for the Investigational New Drug
CI
Fudan-Zhangjiang Bio-Pharmaceutical's Cancer Drug Passes Chinese Regulator’s Consistency Evaluation
MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives Notification of Approval for Supplementary Drug Application
CI
Fudan-Zhangjiang's Profit Drops 70.5% in Q3
MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Moderate to Severe Inflammatory Acne Vulgaris Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)
AQ
Fudan-Zhangjiang Bio Gets Nod for Cancer Drug Trial
MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives Acceptance Notice Issued by the National Medical Products Administration of the PRC
CI
Fudan-Zhangjiang Bio Puchases Structured Deposit Products
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1349 Stock
  4. News Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.